AlzeCure receives payment of EU grant for Phase 2 clinical trial with NeuroRestore ACD856 for Alzheimer's disease

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, announced today that the company has received the first payment of a grant of EUR 2.5 million from the European Innovation Council (EIC). The funding will enable a Phase IIa clinical study with the company's innovative drug candidate NeuroRestore ACD856 for the treatment of Alzheimer's disease.

The grant from the EIC Accelerator will help AlzeCure to conduct important clinical trials where NeuroRestore ACD856 will be tested in patients with Alzheimer's disease. ACD856 is being developed to improve patients' learning and memory function and affect the course of the disease in Alzheimer's disease. ACD856 is a so-called Trk-PAM, a new type of drug that enhances the brain's BDNF and NGF signaling. Impaired function in these signaling pathways is linked to impaired cognition in several different diseases, such as Alzheimer's disease, sleep disorders, traumatic brain injury and Parkinson's disease.

Previous clinical studies have shown that the substance is safe, is effectively absorbed into the brain, and activates neuronal pathways important for both cognition and depression. Preclinical data also shows positive effects on neuronal communication, learning, memory, as well as neuroprotective and anti-inflammatory properties, including improved mitochondrial function.

”ACD856 has a unique mechanism of action and the potential to improve both learning and memory capacity as well as having disease-modifying properties. This is significant for patients with Alzheimer's and other neurodegenerative diseases. The support from the EIC Accelerator is a validation and significant recognition of the project's potential and level of innovation. The grant enables the continued clinical studies and accelerates the development of this much-needed Alzheimer's treatment for patients”, said Johan Sandin, Chief Scientific Officer at AlzeCure Pharma.

”We are very pleased to have received this grant from the EIC, which is a strong validation of our work and crucial for bringing this new treatment to patients. Alzheimer's disease is the most common form of dementia and affects approximately 55 million people globally, and the number of patients is expected to triple over the next 30 years. The disease poses a great burden on both patients, relatives and society, and there is currently a great need for new, effective treatments. With the grant from the EIC, AlzeCure Pharma takes an important step towards being able to offer a new treatment option for this serious disease”, said Martin Jönsson, CEO of AlzeCure Pharma.